First-Line Therapy for Wild-Type Patients

Michael J. Jelinek, Jyoti D. Patel

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

For patients with wild-type lung adenocarcinoma, the options for first-line therapy have significantly expanded in recent years. Improvements in combination chemotherapy, maintenance treatment, patient selection, and addition of antiangiogenic therapy have all modestly improved survival over the past decade. Immune checkpoint modulation with programmed death-1 (PD-1) inhibition has shown considerable promise in fundamentally changing the approach to patients with advanced lung adenocarcinoma. PD-1 inhibition is particularly promising as single agent therapy or in combination with chemotherapy depending on programmed death ligand 1 (PD-L1) expression. Future investigations are combining PD-1/L1 with chemotherapy and other immune-oncology agents in an effort to further improve efficacy.

Original languageEnglish (US)
Title of host publicationPulmonary Adenocarcinoma
Subtitle of host publicationApproaches to Treatment
PublisherElsevier
Pages87-102
Number of pages16
ISBN (Electronic)9780323554336
DOIs
StatePublished - Jan 1 2018

Keywords

  • Adenocarcinoma
  • Bevacizumab
  • Chemotherapy
  • First-line
  • Immunotherapy
  • Lung

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'First-Line Therapy for Wild-Type Patients'. Together they form a unique fingerprint.

Cite this